Bristol-Myers Squibb获得了高达15亿美元的轨道治疗药物,以提升其癌症细胞治疗管道。 Bristol-Myers Squibb acquires Orbital Therapeutics for up to $1.5 billion to boost its cancer cell therapy pipeline.

Bristol-Myers Squibb同意在价值达15亿美元的交易中购买剑桥生物技术轨道治疗设备,包括预付和潜在的里程碑付款。 Bristol-Myers Squibb has agreed to acquire Cambridge-based biotech Orbital Therapeutics in a deal valued at up to $1.5 billion, including upfront and potential milestone payments. 这一收购扩大了布里斯托尔-迈尔斯的细胞治疗管道,增加了Orbital的针对固体瘤的研究CAR-T疗法. The acquisition expands Bristol-Myers' cell therapy pipeline, adding Orbital’s investigational CAR-T therapies targeting solid tumors. 这项交易于2025年10月10日宣布, 标志着该公司在加强肿瘤学组合与下一代免疫疗法的战略上迈出了重大一步。 The deal, announced on October 10, 2025, marks a significant move in the company’s strategy to strengthen its oncology portfolio with next-generation immunotherapies.